Citations

Clear

4847 citation(s) found for "Yu, Eric".

Diagnostic Delay in Human Papillomavirus Negative Oropharyngeal Squamous Cell Carcinoma
Karp, Emily E. , O’Byrne, Thomas J., Lu, Lauren , Routman, David M. , Wittich, Michelle A. Neben, Price, Katharine A. , Tasche, Kendall K. , Moore, Eric J. , Abel, Kathryn M. Van , Yin, Linda X , O'Byrne, Thomas Jamie, Lu, Lauren Y, Routman, David M , Lester, Scott C. , Neben Wittich, Michelle A, Moore, Eric J , Van Abel, Kathryn M , Yin, Linda X. , Daniel, J. , Chintakuntlawar, Ashish V. , Price, Daniel L.

Mayo Clinic

The Laryngoscope | July 19, 2022 | Volume: 133 | Issue: 6 | Pages: 1394-1401

10.1002/lary.30307 | PMID 35851669 Get It

ObjectiveFailure to recognize symptoms of non‐human papillomavirus‐associated oropharyngeal squamous cell carcinoma (HPV(−)OPSCC) at presentation can delay diagnosis and treatment. We aim to identify patient factors and provider practice patterns that delay presentation and care in HPV(−)OPSCC.MethodsRetrospective review at a tertiary care center. Patients with HPV(−)OPSCC receiving treatment from 2006 to 2016. Patients were excluded if their date of symptom onset or diagnosis was unknown after thorough review of the electronic medical record or their tissue was not tested for HPV or p16. Clinical data, workup, and care timelines were abstracted. Univariate and multivariable linear regressions were performed to determine associations between patient and provider factors and delays in care.ResultsOf 70 included patients, 52 (74%) were male and mean age was 60.5 (SD = 9.0). Median time to diagnosis was 69 days (IQR = 32–127 days), with a median latency of 30 days (IQR = 12–61 days) from symptom onset to first presentation and 19.5 days (IQR = 4–46 days) from the first presentation to diagnosis. Most patients visited at least 2 providers (n = 52, 74%) before diagnosis. Evaluation by 3 or more providers prior to diagnosis was associated with significant delays in diagnosis of nearly a year (357.7 days, p < 0.001) and being treated or prescribed analgesia prior to diagnosis was significantly associated with delays in diagnosis (p = 0.004) on univariate regression analysis.ConclusionsDelays in care related to evaluations by multiple providers and misdiagnosis prolonged time to diagnosis in HPV(−)OPSCC. Improved patient and provider education is necessary to expedite the diagnosis of HPV(−)OPSCC.Level of Evidence4 Laryngoscope, 133:1394–1401, 2023
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Tang, Jinyi , Zeng, Cong , Cox, Thomas M, Li, Chaofan , Son, Young Min , Cheon, In Su , Wu, Yue , Taylor, Justin J. , Chakaraborty, Rana, Johnson, Aaron J. , Schiavo, Dante , Utz, James P., Reisenauer, Janani , Midthun, David E. , Mullon, John J., Edell, Eric S. , Alameh, Mohamad‐Gabriel , Borish, Larry , Teague, W. Gerald , Kaplan, Mark H. , Kern, Ryan , Vassallo, Robert , Behl, Supriya, Taylor, Justin J , Chakraborty, Rana , Johnson, Aaron J. , Reisenauer, Janani S , Midthun, David E , Kaplan, Mark H , Weissman, Drew , Kern, R , Hu, Haitao , Vassallo, Robert , Liu, Shan-Lu , Sun, Jie , Tang, J , Li, Chaofan , Behl, Supriya , Chakaraborty, Rana, Liu, Shan-Lu , Sun, Jie

Mayo Clinic

Science Immunology | July 19, 2022 | Volume: 7 | Issue: 76 | Pages: No page available

10.1126/sciimmunol.add4853 | PMID 35857583 Get It

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.
Proximal Scar Progression in Idiopathic Subglottic Stenosis After Wedge Excision: Does it Happen?
Xie, Katherine , Bowen, Andrew J. , Richards, Bradley A. , Aden, Aisha A. , Wiedermann, Joshua P. , Rutt, Amy L. , Vassallo, Robert , Edell, Eric S. , Bayan, Semirra L. , Kasperbauer, Jan L. , Ekbom, Dale C. , Xie, Katherine Z , Bowen, Andrew Jay , Aden, Aisha , Wiedermann, Joshua , Rutt, Amy L. , Vassallo, Robert , Bayan, Semirra

Mayo Clinic

The Laryngoscope | July 18, 2022 | Volume: 133 | Issue: 4 | Pages: 875-882

10.1002/lary.30292 | PMID 35848772 Get It

ObjectiveTo compare the incidence of glottic stenosis in idiopathic subglottic stenosis (iSGS) patients with no prior surgical intervention to those with a history of endoscopic dilation and characterize the incidence of glottic involvement, changes in scar length, and progression of scar toward glottis following laser wedge excision (LWE).MethodsA retrospective review of iSGS patients who underwent LWE between 2002 and 2021 was performed. Patients without prior airway surgery were labeled LWE primary (LWEP) and operative findings for LWEP patients were reviewed for glottic involvement, scar length (DL), and distance from the glottis to superior‐most aspect of scar (DGS). Rates (in mm/procedure) of DΔL, reflecting an increase in length, and D−ΔGS, reflecting proximal migration, were calculated by dividing DΔL and D−ΔGS by the number of LWE procedures.Results213 iSGS patients underwent LWE, with 132 being LWEP patients. LWEP had a lower incidence of baseline glottic involvement (n = 6, 4.5%) than LWE secondary (LWES; n = 6, 7.5%). Four new cases of glottic involvement were noted in LWEP patients following LWE, with only one being clinically significant resulting in permanently decreased vocal fold mobility. With each procedure, scar length increased by 1.0 mm and DGS decreased by 0.7 mm, reflecting a migration or decrease in DGS of 9.5% with each procedure with respect to initial DGS. Overall rates of glottic stenosis following operations were similar between LWEP and LWES cohorts, 7.6% and 7.5% respectively.ConclusionThere appears to be a low risk of glottic involvement resulting from the LWE procedure in iSGS patients.Level of Evidence4 Laryngoscope, 133:875–882, 2023
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer
Nguyen, Duy T. , Yang, Wei , Renganathan, Arun , Weimholt, Cody , Angappulige, Duminduni H. , Nguyen, Thanh , Sprung, Robert W. , Andriole, Gerald L. , Kim, Eric H. , Mahajan, Nupam P. , Mahajan, Kiran

Mayo Clinic

Clinical Cancer Research | July 18, 2022 | Volume: 28 | Issue: 18 | Pages: 4131-4145

10.1158/1078-0432.ccr-21-3603 | PMID 35849143 Get It

Abstract Purpose: Androgen receptor (AR) antagonism is exacerbated by HOXB13 in castration-resistant prostate cancers (CRPC). However, it is unclear when and how HOXB13 primes CRPCs for AR antagonism. By mass-spectrometry analysis of CRPC extract, we uncovered a novel lysine 13 (K13) acetylation in HOXB13 mediated by CBP/p300. To determine whether acetylated K13-HOXB13 is a clinical biomarker of CRPC development, we characterized its role in prostate cancer biology. Experimental Design: We identified tumor-specific acK13-HOXB13 signal enriched super enhancer (SE)-regulated targets. We analyzed the effect of loss of HOXB13K13-acetylation on chromatin binding, SE proximal target gene expression, self-renewal, enzalutamide sensitivity, and CRPC tumor growth by employing isogenic parental and HOXB13K13A mutants. Finally, using primary human prostate organoids, we evaluated whether inhibiting an acK13-HOXB13 target, ACK1, with a selective inhibitor (R)-9b is superior to AR antagonists in inhibiting CRPC growth. Results: acK13-HOXB13 promotes increased expression of lineage (AR, HOXB13), prostate cancer diagnostic (FOLH1), CRPC-promoting (ACK1), and angiogenesis (VEGFA, Angiopoietins) genes early in prostate cancer development by establishing tumor-specific SEs. acK13-HOXB13 recruitment to key SE-regulated targets is insensitive to enzalutamide. ACK1 expression is significantly reduced in the loss of function HOXB13K13A mutant CRPCs. Consequently, HOXB13K13A mutants display reduced self-renewal, increased sensitivity to enzalutamide, and impaired xenograft tumor growth. Primary human prostate tumor organoids expressing HOXB13 are significantly resistant to AR antagonists but sensitive to (R)-9b. Conclusions: In summary, acetylated HOXB13 is a biomarker of clinically significant prostate cancer. Importantly, PSMA-targeting agents and (R)-9b could be new therapeutic modalities to target HOXB13–ACK1 axis regulated prostate cancers.
Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial
Shirk, Joseph D. , Reiter, Robert E. , Wallen, Eric, Pak, Ray , Badani, Ketan K. , Porter, James , Ahlering, Thomas E.

Mayo Clinic

Journal of Urology | July 18, 2022 | Volume: 208 | Issue: 3 | Pages: 618-625

10.1097/ju.0000000000002719 | PMID 35848770 Get It

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas
Katz, Matthew H. G. , Shi, Qian , Meyers, Jeff, Herman, Joseph M. , Chuong, Michael D. , Wolpin, Brian M. , Marsh, Robert , Schwartz, Larry, Behr, Spencer C. , Frankel, Wendy L. , Collisson, Eric A. , Leenstra, James L. , Vaccaro, Gina M. , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , Shi, Qian , Katz, Matthew H G , Ahmad, Syed Ameen , Schwartz, Larry, Williams, Terence M. , Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

JAMA Oncology | July 14, 2022 | Volume: 8 | Issue: 9 | Pages: 1263

10.1001/jamaoncol.2022.2319 | PMID 35834226 Get It

Importance National guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear. Objective To compare treatment with neoadjuvant modified FOLFIRINOX (mFOLFIRINOX) with or without hypofractionated radiation therapy with historical data and establish standards for therapy in borderline resectable PDAC. Design, Setting, and Participants This prospective, multicenter, randomized phase 2 clinical trial conducted from February 2017 to January 2019 among member institutions of National Clinical Trials Network cooperative groups used standardized quality control measures and included 126 patients, of whom 70 (55.6%) were registered to arm 1 (systemic therapy; 54 randomized, 16 following closure of arm 2 at interim analysis) and 56 (44.4%) to arm 2 (systemic therapy and sequential hypofractionated radiotherapy; all randomized before closure). Data were analyzed by the Alliance Statistics and Data Management Center during September 2021. Interventions Arm 1: 8 treatment cycles of mFOLFIRINOX (oxaliplatin, 85 mg/m 2 ; irinotecan, 180 mg/m 2 ; leucovorin, 400 mg/m 2 ; and infusional fluorouracil, 2400 mg/m 2 ) over 46 hours, administered every 2 weeks. Arm 2: 7 treatment cycles of mFOLFIRINOX followed by stereotactic body radiotherapy (33-40 Gy in 5 fractions) or hypofractionated image-guided radiotherapy (25 Gy in 5 fractions). Patients without disease progression underwent pancreatectomy, which was followed by 4 cycles of treatment with postoperative FOLFOX6 (oxaliplatin, 85 mg/m 2 ; leucovorin, 400 mg/m 2 ; bolus fluorouracil, 400 mg/m 2 ; and infusional fluorouracil, 2400 mg/m 2 over 46 hours). Main Outcomes and Measures Each treatment arm’s 18-month overall survival (OS) rate was compared with a historical control rate of 50%. A planned interim analysis mandated closure of either arm for which 11 or fewer of the first 30 accrued patients underwent margin-negative (R0) resection. Results Of 126 patients, 62 (49%) were women, and the median (range) age was 64 (37-83) years. Among the first 30 evaluable patients enrolled to each arm, 17 patients in arm 1 (57%) and 10 patients in arm 2 (33%) had undergone R0 resection, leading to closure of arm 2 but continuation to full enrollment in arm 1. The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2. The median OS of evaluable patients in arm 1 and arm 2 was 29.8 (95% CI, 21.1-36.6) months and 17.1 (95% CI, 12.8-24.4) months, respectively. Conclusions and Relevance This randomized clinical trial found that treatment with neoadjuvant mFOLFIRINOX alone was associated with favorable OS in patients with borderline resectable PDAC compared with mFOLFIRINOX treatment plus hypofractionated radiotherapy; thus, mFOLFIRINOX represents a reference regimen in this setting. Trial Registration ClinicalTrials.gov Identifier: NCT02839343
Descriptive Characteristics and Outcomes of Patients Undergoing Revision Anterior Cruciate Ligament Reconstruction With and Without Tunnel Bone Grafting
Group, MARS, DeFroda, Steven F. , Wright, Rick W. , Huston, Laura J. , Pennings, Jacquelyn S. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Albright, John P., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Brophy, Robert H. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Owens, Brett D. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Benjamin, C. , McAllister, David R. , Shea, Kevin G. , Sherman, Orrin H.

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2022 | Volume: 50 | Issue: 9 | Pages: 2397-2409

10.1177/03635465221104470 | PMID 35833922 Get It

Background: Lytic or malpositioned tunnels may require bone grafting during revision anterior cruciate ligament reconstruction (rACLR) surgery. Patient characteristics and effects of grafting on outcomes after rACLR are not well described. Purpose: To describe preoperative characteristics, intraoperative findings, and 2-year outcomes for patients with rACLR undergoing bone grafting procedures compared with patients with rACLR without grafting. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 1234 patients who underwent rACLR were prospectively enrolled between 2006 and 2011. Baseline revision and 2-year characteristics, surgical technique, pathology, treatment, and patient-reported outcome instruments (International Knee Documentation Committee [IKDC], Knee injury and Osteoarthritis Outcome Score [KOOS], Western Ontario and McMaster Universities Osteoarthritis Index, and Marx Activity Rating Scale [Marx]) were collected, as well as subsequent surgery information, if applicable. The chi-square and analysis of variance tests were used to compare group characteristics. Results: A total of 159 patients (13%) underwent tunnel grafting—64 (5%) patients underwent 1-stage and 95 (8%) underwent 2-stage grafting. Grafting was isolated to the femur in 31 (2.5%) patients, the tibia in 40 (3%) patients, and combined in 88 patients (7%). Baseline KOOS Quality of Life (QoL) and Marx activity scores were significantly lower in the 2-stage group compared with the no bone grafting group ( P≤ .001). Patients who required 2-stage grafting had more previous ACLRs ( P < .001) and were less likely to have received a bone–patellar tendon–bone or a soft tissue autograft at primary ACLR procedure ( P≤ .021) compared with the no bone grafting group. For current rACLR, patients undergoing either 1-stage or 2-stage bone grafting were more likely to receive a bone–patellar tendon–bone allograft ( P≤ .008) and less likely to receive a soft tissue autograft ( P≤ .003) compared with the no bone grafting group. At 2-year follow-up of 1052 (85%) patients, we found inferior outcomes in the 2-stage bone grafting group (IKDC score = 68; KOOS QoL score = 44; KOOS Sport/Recreation score = 65; and Marx activity score = 3) compared with the no bone grafting group (IKDC score = 77; KOOS QoL score = 63; KOOS Sport/Recreation score = 75; and Marx activity score = 7) ( P≤ .01). The 1-stage bone graft group did not significantly differ compared with the no bone grafting group. Conclusion: Tunnel bone grafting was performed in 13% of our rACLR cohort, with 8% undergoing 2-stage surgery. Patients treated with 2-stage grafting had inferior baseline and 2-year patient-reported outcomes and activity levels compared with patients not undergoing bone grafting. Patients treated with 1-stage grafting had similar baseline and 2-year patient-reported outcomes and activity levels compared with patients not undergoing bone grafting.
SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19
Serrano, Geidy E. , Walker, Jessica E. , Tremblay, Cécilia , Huentelman, Matthew J. , Belden, Christine M. , Goldfarb, Danielle, Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caselli, Richard J. , Woodruff, Bryan K. , Haarer, Chadwick F., Ruhlen, Thomas, Nguyen, Steve, Schmitt, Dasan, Rapscak, Steven Z., Bime, Christian , Peters, Joseph L., Alevritis, Ellie, Arce, Richard, Glass, Michael J. , Vargas, Daisy, Sue, Lucia I., Intorcia, Anthony J., Nelson, Courtney M. , Oliver, Javon, Russell, Aryck, Suszczewicz, Katsuko E., Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Hobgood, Holly M, Zhang, Haiyu , Solis, Daniel , Montine, Thomas J. , Berry, Gerald J. , Reiman, Eric M. , Röltgen, Katharina , Boyd, Scott D. , Zehnder, James L. , Desforges, Marc , DeTure, Michael , Beach, Thomas G. , Driver-Dunckley, Erika, Berry, Gerald J , Serrano, Geidy E , Piras, Ignazio Stefano , Shprecher, David , Atri, Alireza , Adler, Charles H. , Haarer, Chadwick F., Torres, Marı́a José , Peters, Joseph L, Mizgerd, Joseph P. , Sahoo, Malaya Kumar , Pinsky, Benjamin A. , Talbot, Pierre J. , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | July 12, 2022 | Volume: 81 | Issue: 9 | Pages: 666-695

10.1093/jnen/nlac056 | PMID 35818336 Get It

Abstract Brains of 42 COVID-19 decedents and 107 non-COVID-19 controls were studied. RT-PCR screening of 16 regions from 20 COVID-19 autopsies found SARS-CoV-2 E gene viral sequences in 7 regions (2.5% of 320 samples), concentrated in 4/20 subjects (20%). Additional screening of olfactory bulb (OB), amygdala (AMY) and entorhinal area for E, N1, N2, RNA-dependent RNA polymerase, and S gene sequences detected one or more of these in OB in 8/21 subjects (38%). It is uncertain whether these RNA sequences represent viable virus. Significant histopathology was limited to 2/42 cases (4.8%), one with a large acute cerebral infarct and one with hemorrhagic encephalitis. Case-control RNAseq in OB and AMY found more than 5000 and 700 differentially expressed genes, respectively, unrelated to RT-PCR results; these involved immune response, neuronal constituents, and olfactory/taste receptor genes. Olfactory marker protein-1 reduction indicated COVID-19-related loss of OB olfactory mucosa afferents. Iba-1-immunoreactive microglia had reduced area fractions in cerebellar cortex and AMY, and cytokine arrays showed generalized downregulation in AMY and upregulation in blood serum in COVID-19 cases. Although OB is a major brain portal for SARS-CoV-2, COVID-19 brain changes are more likely due to blood-borne immune mediators and trans-synaptic gene expression changes arising from OB deafferentation.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Pedrini, Steve , Boonkamp, Lynn, Armstrong, Nicola J. , Luo, Jingqin , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Berman, Sarah , Chhatwal, Jasmeer P. , Graff-Radford, Neill, Day, Gregory S. , Farlow, Martin, Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Perrin, Richard J. , Fagan, Anne M. , Morris, John C. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Luo, Jingqin , Berman, Sarah , Boonkamp, Lynn , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John , Karch, Celeste M. , Cruchaga, Carlos , Farlow, Martin R. , Lee, Jae Hong , McDade, Eric , Mori, Hiroshi , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | July 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v2 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
STOPS
Lund, Sarah , Woerster, Malin, Sawatsky, Adam P. , Dozois, Eric J. , D’Angelo, Anne-Lise D. , D'Angelo, Jonathan D, Kelley, Scott R. , D'Angelo, Anne-Lise D, D’Angelo, Jonathan D.

Mayo Clinic

Annals of Surgery | July 7, 2022 | Volume: 276 | Issue: 2 | Pages: 288-292

10.1097/sla.0000000000005447 | PMID 35797637 Get It

Objective: To investigate the steps faculty surgeons take upon experiencing intraoperative error and synthesize these actions to offer a framework for coping with errors. Background: While intraoperative errors are inevitable, formal training in error recovery is insufficient and there are no established curricula that teach surgeons how to deal with the intraoperative error. This is problematic because insufficient error recovery is detrimental to both patient outcomes and surgeon psychological well-being. Methods: We conducted a thematic analysis. One-hour in-depth semistructured interviews were conducted with faculty surgeons from 3 hospitals. Surgeons described recent experiences with intraoperative error. Interviews were transcribed and coded. Analysis allowed for development of themes regarding responses to errors and coping strategies. Results: Twenty-seven surgeons (30% female) participated. Upon completion of the analysis, themes emerged in 3 distinct areas: (1) Exigency, or a need for training surgical learners how to cope with intraoperative errors, (2) Learning, or how faculty surgeons themselves learned to cope with intraoperative errors, and (3) Responses, or how surgeons now handle intraoperative errors. The latter category was organized into the STOPS framework: Intraoperative errors could produce STOPS: Stop, Talk to your Team, Obtain Help, Plan, Succeed. Conclusions and Relevance: This study provides both novel insight into how surgeons cope with intraoperative errors and a framework that may be of great use to trainees and faculty alike.